A Nervous System-Specific Model of Creatine Transporter Deficiency Recapitulates the Cognitive Endophenotype of the Disease: a Longitudinal Study.
Animals
Brain Diseases, Metabolic, Inborn
/ pathology
Cognitive Dysfunction
/ physiopathology
Creatine
/ deficiency
Disease Models, Animal
Endophenotypes
Mental Retardation, X-Linked
/ pathology
Mice, Inbred C57BL
Neuroglia
/ pathology
Neurons
/ pathology
Plasma Membrane Neurotransmitter Transport Proteins
/ deficiency
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 01 2019
11 01 2019
Historique:
received:
06
06
2018
accepted:
15
11
2018
entrez:
13
1
2019
pubmed:
13
1
2019
medline:
21
1
2020
Statut:
epublish
Résumé
Mutations in creatine (Cr) transporter (CrT) gene lead to cerebral creatine deficiency syndrome-1 (CTD), an orphan neurodevelopmental disorder presenting with brain Cr deficiency, intellectual disability, seizures, movement and autistic-like behavioral disturbances, language and speech impairment. We have recently generated a murine model of CTD obtained by ubiquitous deletion of 5-7 exons in the CrT gene. These mice showed a marked Cr depletion, associated to early and progressive cognitive impairment, and autistic-like defects, thus resembling the key features of human CTD. Given the importance of extraneural dysfunctions in neurodevelopmental disorders, here we analyzed the specific role of neural Cr in the CTD phenotype. We induced the conditional deletion of Slc6a8 gene in neuronal and glial cells by crossing CrT floxed mice with the Nestin::Cre recombinase Tg (Nes-cre) 1Kln mouse. We report that nervous system-specific Cr depletion leads to a progressive cognitive regression starting in the adult age. No autistic-like features, including repetitive and stereotyped movements, routines and rituals, are present in this model. These results indicate that Cr depletion in the nervous system is a pivotal cause of the CTD pathological phenotype, in particular with regard to the cognitive domain, but extraneural actors also play a role.
Identifiants
pubmed: 30635645
doi: 10.1038/s41598-018-37303-1
pii: 10.1038/s41598-018-37303-1
pmc: PMC6329805
doi:
Substances chimiques
Plasma Membrane Neurotransmitter Transport Proteins
0
Creatine
MU72812GK0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Références
Mol Genet Metab. 2010 Dec;101(4):409-12
pubmed: 20846889
Lancet. 1996 Sep 21;348(9030):789-90
pubmed: 8813986
Amino Acids. 2016 Aug;48(8):2057-65
pubmed: 27401086
Mol Genet Metab. 2001 Dec;74(4):413-9
pubmed: 11749046
Oncotarget. 2017 Apr 4;8(14):23539-23550
pubmed: 28212563
Mol Genet Metab. 2002 Dec;77(4):326-31
pubmed: 12468279
Hum Mol Genet. 2016 Oct 1;25(19):4186-4200
pubmed: 27466184
Biochimie. 2015 Dec;119:146-65
pubmed: 26542286
J Clin Invest. 2012 Aug;122(8):2837-46
pubmed: 22751104
F1000Res. 2014 Sep 29;3:228
pubmed: 25485098
Mol Genet Metab. 2014 Aug;112(4):259-74
pubmed: 24953403
J Inherit Metab Dis. 2014 Sep;37(5):715-33
pubmed: 24789340
Neurocase. 2008;14(2):151-61
pubmed: 18569740
Ann N Y Acad Sci. 2018 May;1420(1):5-25
pubmed: 28768369
J Inherit Metab Dis. 2012 Jan;35(1):151-7
pubmed: 21660517
J Inherit Metab Dis. 2014 Jan;37(1):63-8
pubmed: 23716276
J Inherit Metab Dis. 2012 Jan;35(1):141-9
pubmed: 21556832
Mol Cell Biochem. 2004 Jul;262(1-2):35-9
pubmed: 15532707
Nat Genet. 1999 Sep;23(1):99-103
pubmed: 10471508
FASEB J. 2013 Oct;27(10):4147-56
pubmed: 23825223
Pediatr Neurol. 2015 Oct;53(4):360-363.e2
pubmed: 26205312
PLoS One. 2011 Jan 13;6(1):e16187
pubmed: 21249153
J Psychiatr Res. 2014 Aug;55:87-95
pubmed: 24768109
Mol Cell Biochem. 2003 Feb;244(1-2):45-8
pubmed: 12701808
Front Neurosci. 2016 Feb 09;10:27
pubmed: 26903795
Cell. 2014 Jul 3;158(1):198-212
pubmed: 24995986
Genes Brain Behav. 2018 Jul;17(6):e12461
pubmed: 29384270
Mol Cell Neurosci. 2013 Mar;53:69-76
pubmed: 23069728
Anal Biochem. 2005 Aug 15;343(2):356-8
pubmed: 15978539